MARKET NEWS

 

Gerresheimer Builds New Production Plant for Plastic Containers in India
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion
WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA
Silo Pharma Inc. Receives $1 Million in Up Front Licensing Deal 
EMA Recommends COVID-19 Vaccine Moderna for Authorization in the EU
Apollomics & GlycoMimetics Granted Breakthrough Therapy Designation

  FEATURED EDITORIAL

 

  COMPANY PROFILE

AbbVie is devoted to the discovery, development, manufacturing, and marketing of products that span the continuum of care in pharmaceutical therapies. Leading-edge science and technologies that hold the potential for improving lives are advanced through AbbVie’s dedication to research. Our uniqueness is created by the work we do – producing innovative medicines, continually investing in our pipeline, and giving back to create healthier, more vibrant communities. We have sustained our success by staying true to the key principles on which our company was forged: innovative care and a desire to make a meaningful difference in all that we do. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SIRION Biotech GmbH Licensed LentiBOOST™ Transduction Technology to Cellectis

SIRION Biotech GmbH Licensed LentiBOOST™ Transduction Technology to Cellectis

Through this recent license agreement, SIRION Biotech GmbH has granted Cellectis non-exclusive right under its proprietary lentiviral transduction….

Servier & X-Chem Announce Drug Discovery Collaboration 

Servier & X-Chem Announce Drug Discovery Collaboration 

Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….

Kite & Oxford BioTherapeutics Establish Cell Therapy Research Collaboration

Kite & Oxford BioTherapeutics Establish Cell Therapy Research Collaboration

Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….

Argenx & Zai Lab Announce Strategic Collaboration 

Argenx & Zai Lab Announce Strategic Collaboration 

Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 20 – Drug Delivery
January 27 – Bioavailability